The New York Entrepreneur

Dow Jones Newswires: AstraZeneca Enhertu breast cancer drug is recommended for EU approval

Read Time:8 Second

The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post The Moneyist: ‘She has a poor work ethic’: I rent out rooms in a single-family home. I charge $1,300 per room, but my sister only pays $800. Should I ask her to pay more?
Next post Dow Jones Newswires: Ipsen to acquire U.S.-based Epizyme for $247 million.